Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last
30 years, however, overall prognosis remains poor with median survival of 2 to 3 years. Long
term complete responses are observed only for a minority of MBC patients (2-5%) and MBC
remains an incurable disease for most patients. Eribulin is a chemotherapy approved by the US
FDA in November of 2010 to treat patients with MBC who have received at least two prior
chemotherapy regimens. In this research study, the investigators are looking to see how well
eribulin helps participants with MBC in an earlier-line setting. Eribulin works by
interfering with cancer cell division, growth and spread.